Artivion (NYSE:AORT) Shares Gap Up – Here’s Why

Artivion, Inc. (NYSE:AORT)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $26.53, but opened at $27.21. Artivion shares last traded at $27.55, with a volume of 34,778 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have commented on AORT shares. Oppenheimer boosted their price objective on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Lake Street Capital upped their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Stifel Nicolaus upped their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price target on shares of Artivion in a report on Friday, September 27th. Finally, JMP Securities initiated coverage on shares of Artivion in a research report on Wednesday. They set an “outperform” rating and a $33.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion currently has an average rating of “Buy” and an average price target of $30.60.

Artivion Stock Up 2.9 %

The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -110.54 and a beta of 1.74. The stock’s fifty day moving average is $25.80 and its two-hundred day moving average is $24.58.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.03 by $0.04. The firm had revenue of $98.02 million during the quarter, compared to analyst estimates of $97.70 million. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. Sell-side analysts predict that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Artivion

In other news, CAO Amy Horton sold 12,430 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the transaction, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the transaction, the director now directly owns 34,159 shares in the company, valued at $853,633.41. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,109 shares of company stock worth $951,935. Insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

A number of hedge funds have recently made changes to their positions in the stock. Creative Planning lifted its holdings in shares of Artivion by 182.1% during the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock worth $762,000 after acquiring an additional 18,486 shares during the last quarter. SG Americas Securities LLC bought a new stake in Artivion in the third quarter worth $450,000. Perceptive Advisors LLC lifted its stake in Artivion by 4.7% in the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after purchasing an additional 124,725 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock worth $392,000 after purchasing an additional 481 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Artivion in the second quarter worth $366,000. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.